JUST WHAT CATS ORDERED A convenient, once-daily
liquid oral solution for feline diabetes
Simplify feline diabetes treatment for cats and their owners with the liberating convenience of a once-daily liquid oral solution.
• Delivers sustained glycemic control starting as soon as 1 week for most cats 1,2 • Precise dosing tailored to the cat’s weight • Minimal risk of clinical hypoglycemic events 1-3 • Well accepted by most cats 1
3 Months’ Supply*
Scan for more details!
IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. Before using this product, it is important to read the entire product insert, including the boxed warning. Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO. Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Keep SENVELGO in a secure location out of reach of children , dogs, cats, and other animals to avoid accidental ingestion or overdose. For more information, please refer to the enclosed package insert or visit SENVELGOClinic.com. *Based on average cat weight of 11 lbs 1. Data on file at Boehringer Ingelheim. 2. SENVELGO® (velagliflozin oral solution) [Freedom of Information Summary; NADA 141-568]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2023. 3. SENVELGO® (velagliflozin oral solution) prescribing information.
SENVELGO® and the SENVELGO Logo® are registered trademarks of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0537-2023-B-V2
Made with FlippingBook - PDF hosting